Abstract
EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.
Original language | English |
---|---|
Pages (from-to) | 965-968 |
Number of pages | 4 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 81 |
Issue number | 5 |
DOIs | |
State | Published - May 2018 |
Keywords
- Carbazoles/pharmacology
- Carcinoma, Squamous Cell/drug therapy
- Crizotinib/pharmacology
- Genetic Testing
- Humans
- Lung Neoplasms/drug therapy
- Male
- Middle Aged
- Oncogene Proteins, Fusion/antagonists & inhibitors
- Patient Selection
- Piperidines/pharmacology
- Smoking/adverse effects
- Treatment Outcome